Company Description
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States.
It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging.
It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report.
The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC.
| Country | United States |
| Founded | 2019 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Mark Brian White |
Contact Details
Address: 729 Washington Ave. N, Suite 600 Minneapolis, Minnesota 55401 United States | |
| Phone | (612) 562-9447 |
| Website | foxotechnologies.com |
Stock Details
| Ticker Symbol | FOXO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001812360 |
| ISIN Number | US3514713052 |
| Employer ID | 85-1050265 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Mark Brian White | Interim Chief Executive Officer and Director |
| Martin Christopher Ward FCA | Interim Chief Financial Officer |
| Jim Grauel Jr. | Chief Distribution Officer |
| Susan Neo | Chief Security Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 20, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 12, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 8, 2024 | 424B3 | Prospectus |
| Feb 8, 2024 | 424B3 | Prospectus |